Trupanion Reports Fourth Quarter and Full Year 2021 Results

Rhea-AI Summary

Trupanion (Nasdaq: TRUP) reported strong financial results for Q4 and the full year 2021, with total revenue of $699 million, up 39% from 2020. The company enrolled 1,176,778 pets, a 36% increase, while subscription revenue hit $494.9 million, marking a 28% rise. Despite a net loss of $35.5 million, attributed to increased stock-based compensation and acquisition costs, adjusted EBITDA was $4.7 million. The fourth quarter saw a revenue increase to $194.4 million, with a net loss of $7 million but improved adjusted EBITDA of $3.5 million.

Positive

• Total revenue rose to $699 million in 2021, a 39% increase.
• Total enrolled pets reached 1,176,778, up 36% from the previous year.
• Subscription business revenue grew to $494.9 million, a 28% increase.
• Adjusted EBITDA improved to $4.7 million, despite a net loss.

Negative

• Net loss increased to $35.5 million in 2021, compared to $5.8 million in 2020.
• Free cash flow was negative at $(4.9) million, down from $14.1 million in 2020.
• Increased stock-based compensation impacted earnings per share by $0.48.

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2021.

“Our 60 month plan is off to a great start, as shown in our strong year-over-year growth metrics,” said Darryl Rawlings, founder and CEO of Trupanion. “In 2021, we added a record number of new pets while sustaining high-levels of retention, and maintaining scale in our subscription business. As a result, we were able to grow the funds generated from our existing pets by 37% and deploy 56% more capital year-over-year to acquire new pets at strong internal rates of return.”

Full Year 2021 Financial and Business Highlights

• Total revenue was $699.0 million, an increase of 39% compared to 2020.
• Total enrolled pets (including pets from our other business segment) was 1,176,778 at December 31, 2021, an increase of 36% over 2020.
• Subscription business revenue was $494.9 million, an increase of 28% compared to 2020.
• Subscription enrolled pets was 704,333 at December 31, 2021, an increase of 22% over 2020.
• Net loss was $(35.5) million, or $(0.89) per basic and diluted share, compared to net loss of $(5.8) million, or $(0.16) per basic and diluted share, in 2020. Net loss per share was impacted by $0.48 due to an increase in stock-based compensation and by $0.12 due to an increase in depreciation and amortization when compared to the prior-year period. The remaining year-over-year change in earnings per share primarily reflects the Company’s accelerated growth and associated acquisition spend in 2021.
• Adjusted EBITDA was $4.7 million, compared to adjusted EBITDA of $11.5 million in 2020.
• Operating cash flow was $7.5 million and free cash flow was $(4.9) million in 2021. This compared to operating cash flow of $21.5 million and free cash flow of $14.1 million in 2020.
  

Fourth Quarter 2021 Financial and Business Highlights

• Total revenue was $194.4 million, an increase of 36% compared to the fourth quarter of 2020.
• Subscription business revenue was $134.1 million, an increase of 26% compared to the fourth quarter of 2020 (25% on a constant currency basis).
• Net loss was $(7.0) million, or $(0.17) per basic and diluted share, compared to net loss of $(3.5) million, or $(0.09) per basic and diluted share, in the fourth quarter of 2020. Net loss per share was impacted by $0.10 due to an increase in stock-based compensation and by $0.01 due to an increase in depreciation and amortization when compared to the prior year-period.  
• Adjusted EBITDA was $3.5 million, compared to adjusted EBITDA of $2.2 million in the fourth quarter of 2020.
• Operating cash flow was $5.2 million and free cash flow was $1.3 million in the fourth quarter of 2021. This is compared to operating cash flow of $4.0 million and free cash flow of $1.0 million in the fourth quarter of 2020.
  

Revenue by Quarter

A chart accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/d04ecfb3-ce86-4884-8f83-cb66298373fd

Conference Call
Trupanion’s management will host a conference call today to review its fourth quarter and full year 2021 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-877-407-0784 (United States) or 1-201-689-8560 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 13726158.

About Trupanion
Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada and Australia with over 700,000 pets enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its proprietary software, Trupanion is the only provider with the technology to pay veterinarians directly in minutes at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. Trupanion Australia is a partnership between Trupanion and Hollard Insurance Company. For more information, please visit trupanion.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, implement its alliance with Aflac and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls, including over financial reporting; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to successfully implement our alliance with Aflac; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; and our ability to retain key personnel.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequently filed reports on Forms 10-Q and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at www.sec.gov or the Investor Relations section of Trupanion’s website at http://investors.trupanion.com.

Non-GAAP Financial Measures
Trupanion’s stated results may include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

Trupanion, Inc. Consolidated Statements of Operations (in thousands, except share data)
	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
	(unaudited)
Revenue:
Subscription business	$	134,120			$	106,416			$	494,862			$	387,732
Other business		60,259				36,271				204,129				114,296
Total revenue		194,379				142,687				698,991				502,028
Cost of revenue:
Subscription business(1)		108,627				85,761				407,664				314,875
Other business		55,217				33,333				186,981				105,252
Total cost of revenue(2)		163,844				119,094				594,645				420,127
Operating expenses:
Technology and development(1)		4,665				3,108				16,866				9,947
General and administrative(1)		8,996				6,502				31,893				21,847
New pet acquisition expense(1)		19,845				14,809				78,647				47,837
Depreciation and amortization		2,770				2,301				11,965				7,071
Total operating expenses		36,276				26,720				139,371				86,702
Loss from investment in joint venture		(22	)			(42	)			(171	)			(126	)
Operating loss		(5,763	)			(3,169	)			(35,196	)			(4,927	)
Interest expense		9				337				10				1,381
Other expense (income), net		236				(48	)			14				(581	)
Loss before income taxes		(6,008	)			(3,458	)			(35,220	)			(5,727	)
Income tax expense		1,034				44				310				113
Net loss	$	(7,042	)		$	(3,502	)		$	(35,530	)		$	(5,840	)
Net loss per share:
Basic and diluted	$	(0.17	)		$	(0.09	)		$	(0.89	)		$	(0.16	)
Weighted average shares of common stock outstanding:
Basic and diluted		40,413,434				37,841,055				40,137,505				35,858,869
(1)Includes stock-based compensation expense as follows:	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Cost of revenue	$	1,379			$	526			$	7,148			$	1,586
Technology and development		843				392				3,056				758
General and administrative		2,450				883				8,862				3,795
New pet acquisition expense		2,136				801				9,160				2,773
Total stock-based compensation expense	$	6,808			$	2,602			$	28,226			$	8,912
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:
	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Veterinary invoice expense	$	132,852			$	98,169			$	486,062			$	351,124
Other cost of revenue		30,992				20,925				108,583				69,003
Total cost of revenue	$	163,844			$	119,094			$	594,645			$	420,127

Trupanion, Inc. Consolidated Balance Sheets (in thousands, except share data)
	December 31, 2021				December 31, 2020
Assets
Current assets:
Cash and cash equivalents	$	87,400			$	139,878
Short-term investments		126,012				89,862
Accounts and other receivables, net of allowance for doubtful accounts of $342 and $271		165,217				99,065
Prepaid expenses and other assets		12,325				8,222
Total current assets		390,954				337,027
Restricted cash		13,469				6,319
Long-term investments, at fair value		7,061				5,566
Property and equipment, net		77,950				72,602
Intangible assets, net		22,663				27,134
Other long-term assets		17,776				16,557
Goodwill		32,709				33,045
Total assets	$	562,582			$	498,250
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	8,952			$	6,059
Accrued liabilities and other current liabilities		28,162				22,864
Reserve for veterinary invoices		39,671				28,929
Deferred revenue		146,911				92,547
Total current liabilities		223,696				150,399
Deferred tax liabilities		2,827				4,705
Other liabilities		3,859				3,207
Total liabilities		230,382				158,311
Stockholders’ equity:
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 41,408,350 and 40,475,185 shares issued and outstanding at December 31, 2021; 40,383,972 and 39,450,807 shares issued and outstanding at December 31, 2020		—				—
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding		—				—
Additional paid-in capital		466,792				439,007
Accumulated other comprehensive loss		3,077				3,071
Accumulated deficit		(126,890	)			(91,360	)
Treasury stock, at cost: 933,165 shares at December 31, 2021 and 2020		(10,779	)			(10,779	)
Total stockholders’ equity		332,200				339,939
Total liabilities and stockholders’ equity	$	562,582			$	498,250

Trupanion, Inc. Consolidated Statements of Cash Flows (in thousands)
	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
	(unaudited)
Operating activities
Net loss	$	(7,042	)		$	(3,502	)		$	(35,530	)		$	(5,840	)
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation and amortization		2,770				2,301				11,965				7,071
Stock-based compensation expense		6,808				2,602				28,226				8,912
Other, net		(996	)			35				(1,927	)			153
Changes in operating assets and liabilities:
Accounts and other receivables		(7,397	)			(5,204	)			(66,170	)			(43,272	)
Prepaid expenses and other assets		(1,133	)			(860	)			(3,055	)			(2,839	)
Accounts payable, accrued liabilities, and other liabilities		4,443				3,349				8,796				9,951
Reserve for veterinary invoices		914				(30	)			10,768				7,662
Deferred revenue		6,789				5,273				54,385				39,746
Net cash provided by operating activities		5,156				3,964				7,458				21,544
Investing activities
Purchases of investment securities		(33,384	)			(21,314	)			(95,672	)			(65,286	)
Maturities of investment securities		18,803				14,249				57,869				44,066
Cash paid in business acquisition, net of cash acquired		—				(48,133	)			—				(48,133	)
Purchases of property, equipment and intangible assets		(3,818	)			(2,939	)			(12,355	)			(7,451	)
Other		(1,707	)			(31	)			(1,755	)			57
Net cash used in investing activities		(20,106	)			(58,168	)			(51,913	)			(76,747	)
Financing activities
Proceeds from issuance of common stock, net of issuance costs		—				192,265				—				192,265
Proceeds from exercise of stock options		551				1,717				3,607				6,013
Shares withheld to satisfy tax withholding		(1,002	)			(459	)			(4,732	)			(1,115	)
Borrowings from line of credit, net of financing fees		—				—				—				6,213
Repayments to line of credit		—				(29,950	)			—				(32,450	)
Other financing		—				—				—				(78	)
Net cash (used in) provided by financing activities		(451	)			163,573				(1,125	)			170,848
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net		305				198				252				(16	)
Net change in cash, cash equivalents, and restricted cash		(15,096	)			109,567				(45,328	)			115,629
Cash, cash equivalents, and restricted cash at beginning of period		115,965				36,630				146,197				30,568
Cash, cash equivalents, and restricted cash at end of period	$	100,869			$	146,197			$	100,869			$	146,197

The following tables set forth our key operating metrics:
	Year Ended December 31,
		2021				2020
Total Business:
Total pets enrolled (at period end)		1,176,778				862,928
Subscription Business:
Total subscription pets enrolled (at period end)		704,333				577,957
Monthly average revenue per pet	$	63.56			$	60.37
Lifetime value of a pet, including fixed expenses	$	717			$	653
Average pet acquisition cost (PAC)	$	287			$	247
Average monthly retention		98.74	%			98.71	%
	Three Months Ended
	Dec. 31, 2021				Sept. 30, 2021				Jun. 30, 2021				Mar. 31, 2021				Dec. 31, 2020				Sept. 30, 2020				Jun. 30, 2020				Mar. 31, 2020
Total Business:
Total pets enrolled (at period end)		1,176,778				1,104,376				1,024,226				943,854				862,928				804,251				744,727				687,435
Subscription Business:
Total subscription pets enrolled (at period end)		704,333				676,463				643,395				609,835				577,957				552,909				529,400				508,480
Monthly average revenue per pet	$	63.89			$	63.60			$	63.69			$	62.97			$	62.03			$	60.87			$	59.40			$	58.96
Lifetime value of a pet, including fixed expenses	$	717			$	697			$	681			$	684			$	653			$	615			$	597			$	535
Average pet acquisition cost (PAC)	$	306			$	280			$	284			$	279			$	272			$	261			$	199			$	247
Average monthly retention		98.74	%			98.72	%			98.72	%			98.73	%			98.71	%			98.69	%			98.66	%			98.59	%

The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):
	Three Months Ended December 31,								Year Ended December 31,
		2021				2020				2021				2020
Net cash provided by operating activities	$	5,156			$	3,964			$	7,458			$	21,544
Purchases of property and equipment		(3,818	)			(2,939	)			(12,355	)			(7,451	)
Free cash flow	$	1,338			$	1,025			$	(4,897	)		$	14,093

The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands, except percentages):
		Three Months Ended December 31,								Year Ended December 31,
			2021				2020				2021				2020
Veterinary invoice expense		$	132,852			$	98,169			$	486,062			$	351,124
Excluding:
Stock-based compensation expense			(798	)			(358	)			(4,538	)			(1,118	)
Other business cost of paying veterinary invoices			(38,009	)			(22,254	)			(129,614	)			(72,119	)
Subscription cost of paying veterinary invoices		$	94,045			$	75,557			$	351,910			$	277,887
% of subscription revenue			70.1	%			71.0	%			71.1	%			71.7	%
Other cost of revenue		$	30,992			$	20,925			$	108,583			$	69,003
Excluding:
Stock-based compensation expense			(581	)			(168	)			(2,610	)			(468	)
Other business variable expenses			(17,208	)			(11,079	)			(57,367	)			(33,133	)
Subscription variable expenses		$	13,203			$	9,678			$	48,606			$	35,402
% of subscription revenue			9.8	%			9.1	%			9.8	%			9.1	%
Technology and development expense		$	4,665			$	3,108			$	16,866			$	9,947
General and administrative expense			8,996				6,502				31,893				21,847
Excluding:
Stock-based compensation expense			(3,293	)			(1,275	)			(11,918	)			(4,553	)
Development expenses1			(858	)			(339	)			(3,719	)			(339	)
Business combination transaction costs2			—				(522	)			(82	)			(522	)
Fixed expenses		$	9,510			$	7,474			$	33,040			$	26,380
% of total revenue			4.9	%			5.2	%			4.7	%			5.3	%
New pet acquisition expense		$	19,845			$	14,809			$	78,647			$	47,837
Excluding:
Stock-based compensation expense			(2,136	)			(801	)			(9,160	)			(2,773	)
Other business pet acquisition expense			(76	)			(201	)			(499	)			(820	)
Subscription acquisition cost		$	17,633			$	13,807			$	68,988			$	44,244
% of subscription revenue			13.1	%			13.0	%			13.9	%			11.4	%
Technology and development		$	4,665			$	3,108			$	16,866			$	9,947
Excluding:
Stock-based compensation expense			(843	)			(392	)			(3,056	)			(758	)
Technology expenses			(2,964	)			(2,377	)			(10,091	)			(8,850	)
Development expenses1		$	858			$	339			$	3,719			$	339
% of subscription revenue			0.4	%			0.2	%			0.5	%			0.1	%
1As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from pet acquisition spend.
2These one-time expenses related to our acquisition of a software business, primarily related to legal and transaction costs incurred.

The following tables reflect the reconciliation of new pet acquisition expense, previously called “sales and marketing”, to acquisition cost and net acquisition cost (in thousands):
	Year Ended December 31,
		2021				2020
New pet acquisition expense	$	78,647			$	47,837
Excluding:
Stock-based compensation expense		(9,160	)			(2,773	)
Acquisition cost		69,487				45,064
Net of:
Sign-up fee revenue		(4,954	)			(3,292	)
Other business segment pet acquisition expense		(499	)			(820	)
Net acquisition cost	$	64,034			$	40,952
	Three Months Ended
	Dec. 31, 2021				Sept. 30, 2021				Jun. 30, 2021				Mar. 31, 2021				Dec. 31, 2020				Sept. 30, 2020				Jun. 30, 2020				Mar. 31, 2020
New pet acquisition expense	$	19,845			$	19,708			$	19,390			$	19,704			$	14,809			$	13,344			$	9,242			$	10,442
Excluding:
Stock-based compensation expense		(2,136	)			(2,112	)			(2,181	)			(2,731	)			(801	)			(741	)			(675	)			(556	)
Acquisition cost		17,709				17,596				17,209				16,973				14,008				12,603				8,567				9,886
Net of:
Sign-up fee revenue		(1,162	)			(1,268	)			(1,260	)			(1,264	)			(919	)			(827	)			(781	)			(765	)
Other business segment pet acquisition expense		(76	)			(134	)			(118	)			(171	)			(201	)			(265	)			(191	)			(163	)
Net acquisition cost	$	16,471			$	16,194			$	15,831			$	15,538			$	12,888			$	11,511			$	7,595			$	8,958

The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands):
	Year Ended December 31,
		2021				2020
Net loss	$	(35,530	)		$	(5,840	)
Excluding:
Stock-based compensation expense		28,226				8,912
Depreciation and amortization expense		11,965				7,071
Interest income		(337	)			(628	)
Interest expense		10				1,381
Other non-operating expenses		2				99
Income tax expense		310				113
Business combination transaction costs		82				522
(Gain) loss from equity method investment		6				(117	)
Adjusted EBITDA	$	4,734			$	11,513
	Three Months Ended
	Dec. 31, 2021				Sept. 30, 2021				Jun. 30, 2021				Mar. 31, 2021				Dec. 31, 2020				Sept. 30, 2020				Jun. 30, 2020				Mar. 31, 2020
Net income (loss)	$	(7,042	)		$	(6,819	)		$	(9,221	)		$	(12,448	)		$	(3,502	)		$	(2,558	)		$	1,353			$	(1,133	)
Excluding:
Stock-based compensation expense		6,808				6,443				6,527				8,448				2,602				2,430				2,227				1,653
Depreciation and amortization expense		2,770				2,944				3,158				3,093				2,301				1,666				1,723				1,381
Interest income		(80	)			(85	)			(84	)			(88	)			(83	)			(74	)			(134	)			(337	)
Interest expense		9				—				3				(2	)			337				324				341				379
Other non-operating expenses		—				(1	)			3				—				1				2				44				52
Income tax expense (benefit)		1,034				(312	)			(195	)			(217	)			44				26				17				26
Business combination transaction costs		—				—				—				82				522				—				—				—
(Gain) loss from equity method investment		—				—				6				—				—				—				(117	)			—
Adjusted EBITDA	$	3,499			$	2,170			$	197			$	(1,132	)		$	2,222			$	1,816			$	5,454			$	2,021

Contacts:

Investors:
Laura Bainbridge, Vice President, Corporate Communications
206.607.1929
InvestorRelations@trupanion.com

FAQ

What were Trupanion's financial results for Q4 2021?

Trupanion reported total revenue of $194.4 million in Q4 2021, a 36% increase compared to Q4 2020.

How many pets were enrolled by Trupanion by the end of 2021?

Trupanion enrolled 1,176,778 pets by December 31, 2021, a 36% increase from 2020.

What was Trupanion's net loss in 2021?

Trupanion reported a net loss of $(35.5) million in 2021.

What was the subscription revenue for Trupanion in 2021?

Trupanion's subscription revenue reached $494.9 million in 2021, up 28% from the previous year.

How did Trupanion's adjusted EBITDA change in 2021?

Adjusted EBITDA was $4.7 million in 2021, down from $11.5 million in 2020.